SG171602A1 - Use of antisecretory factors for treating intraocular hypertension - Google Patents

Use of antisecretory factors for treating intraocular hypertension

Info

Publication number
SG171602A1
SG171602A1 SG201102876-8A SG2011028768A SG171602A1 SG 171602 A1 SG171602 A1 SG 171602A1 SG 2011028768 A SG2011028768 A SG 2011028768A SG 171602 A1 SG171602 A1 SG 171602A1
Authority
SG
Singapore
Prior art keywords
antisecretory
intraocular hypertension
antisecretory factors
factors
prevention
Prior art date
Application number
SG201102876-8A
Other languages
English (en)
Inventor
Hans-Arne Hansson
Stefan Lange
Eva Jennische
Original Assignee
Lantmaennen As Faktor Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantmaennen As Faktor Ab filed Critical Lantmaennen As Faktor Ab
Publication of SG171602A1 publication Critical patent/SG171602A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SG201102876-8A 2006-04-27 2007-04-27 Use of antisecretory factors for treating intraocular hypertension SG171602A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0600932 2006-04-27

Publications (1)

Publication Number Publication Date
SG171602A1 true SG171602A1 (en) 2011-06-29

Family

ID=38561776

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201102876-8A SG171602A1 (en) 2006-04-27 2007-04-27 Use of antisecretory factors for treating intraocular hypertension

Country Status (18)

Country Link
US (2) US8207296B2 (es)
EP (2) EP2468292B8 (es)
JP (2) JP5284948B2 (es)
KR (1) KR20090040404A (es)
CN (2) CN102633863B (es)
AU (1) AU2007244004B2 (es)
BR (1) BRPI0710959B8 (es)
CA (2) CA2771087C (es)
DK (2) DK2468292T3 (es)
ES (2) ES2773945T3 (es)
IL (1) IL194773A (es)
MX (1) MX2008013769A (es)
NZ (2) NZ572255A (es)
PL (2) PL2015767T3 (es)
RU (1) RU2458703C2 (es)
SG (1) SG171602A1 (es)
WO (1) WO2007126364A2 (es)
ZA (1) ZA200809115B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2015767T3 (pl) * 2006-04-27 2016-05-31 Lantmaennen As Faktor Ab Zastosowanie czynnika przeciwwydzielniczego do leczenia nadciśnienia śródgałkowego
US9962424B2 (en) 2007-04-27 2018-05-08 Lantmännen As-Faktor Ab Use of antisecretory factors (AF) for optimizing cellular uptake
EP2396024A4 (en) * 2009-02-11 2013-02-27 Lantmaennen As Faktor Ab USE OF ANTISECRREATORY FACTORS (AF) FOR OPTIMIZATION OF CELLULAR ABSORPTION
WO2013050795A1 (en) * 2011-10-03 2013-04-11 Femtonics Kft. Use of photoactive compounds
CA3036216A1 (en) * 2012-12-20 2014-06-26 Lantmannen As-Faktor Ab Use of antisecretory factor (af) in glioblastoma treatment
CN107949392B (zh) * 2015-07-10 2022-10-11 兰特门内阿斯-法克托尔公司 用于生产含高含量af-16的蛋黄的方法
JP6999638B2 (ja) 2016-07-18 2022-01-18 ラントメネン・メディカル・アーベー 抗分泌性因子１７
CA3103164A1 (en) 2018-06-28 2020-01-02 Lantmannen Medical Ab Antisecretory factor for use in treatment and/or prevention of acute respiratory failure
WO2020065091A1 (en) 2018-09-28 2020-04-02 Lantmännen Functional Foods Ab A consumable product comprising malted wheat
WO2020065089A2 (en) 2018-09-28 2020-04-02 Lantmännen Functional Foods Ab A consumable product comprising malted dehulled oat
CN115605214A (zh) 2020-03-26 2023-01-13 兰特门内保健食品公司（Se） 用于促进身体活动恢复的包含麦芽化谷物的可消耗产品
US20240148709A1 (en) * 2022-11-08 2024-05-09 Aisa Pharma, Inc. Methods of treating eye pain and eye disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH682716A5 (de) 1992-01-13 1993-11-15 Christian Fricker Benzo-Pyrone und/oder Dobesilat-Calcium enthaltende pharmazeutische Zusammensetzung.
US5585401A (en) * 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
SE508609C2 (sv) * 1995-08-24 1998-10-19 Rural Patent Svenska Ab Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning
AU732508B2 (en) * 1996-01-26 2001-04-26 Governing Council Of The University Of Toronto, The Nucleic acids and proteins related to Alzheimer's disease, and uses therefor
SE9604251L (sv) 1996-11-20 1997-12-22 Svenska Lantmaennen Riksfoerbu Födoämne som vid förtäring inducerar antisekretoriska proteiner
SE513496C2 (sv) * 1998-12-17 2000-09-18 Rural Patent Svenska Ab NASP-berikad äggula samt dess användning
CN1335887A (zh) * 1999-06-21 2002-02-13 印坎药物股份有限公司 血管抑制素∶一种Cys－Ser－Val－Thr－Cys－Gly特异性肿瘤细胞粘附受体
RU2192898C1 (ru) * 2001-08-16 2002-11-20 Московский научно-исследовательский институт глазных болезней им. Гельмгольца Способ лечения герпетического кератита с изъязвлением
GB0322645D0 (en) 2003-09-26 2003-10-29 Melacure Therapeutics Ab Use of antisecretory factor peptides
MX2008013777A (es) * 2006-04-27 2009-02-03 Lantmaennen As Faktor Ab Usos medicos adicionales de la proteina antisecretora.
PL2015767T3 (pl) * 2006-04-27 2016-05-31 Lantmaennen As Faktor Ab Zastosowanie czynnika przeciwwydzielniczego do leczenia nadciśnienia śródgałkowego
BRPI0710858A2 (pt) * 2006-04-27 2011-05-17 Lantmonnen As Faktor Ab uso de uma proteìna anti-secretora, um derivado, homólogo e/ou fragmento da mesma, tendo atividade anti-secretora, e/ou um sal farmaceuticamente ativo da mesma

Also Published As

Publication number Publication date
AU2007244004B2 (en) 2012-02-09
PL2468292T3 (pl) 2020-08-24
IL194773A0 (en) 2011-08-01
ES2561945T3 (es) 2016-03-01
CA2771087C (en) 2016-03-15
RU2458703C2 (ru) 2012-08-20
CA2650344A1 (en) 2007-11-08
WO2007126364A8 (en) 2009-07-23
IL194773A (en) 2015-07-30
ES2773945T3 (es) 2020-07-15
NZ598426A (en) 2012-08-31
RU2008146733A (ru) 2010-06-10
BRPI0710959A2 (pt) 2012-02-28
EP2468292A1 (en) 2012-06-27
EP2468292B8 (en) 2020-02-26
KR20090040404A (ko) 2009-04-24
US8207296B2 (en) 2012-06-26
BRPI0710959B8 (pt) 2021-05-25
BRPI0710959B1 (pt) 2018-11-06
DK2015767T3 (en) 2016-02-08
JP5284948B2 (ja) 2013-09-11
JP2012153695A (ja) 2012-08-16
PL2015767T3 (pl) 2016-05-31
EP2015767A2 (en) 2009-01-21
WO2007126364A2 (en) 2007-11-08
CA2650344C (en) 2017-10-31
EP2015767B1 (en) 2016-01-06
WO2007126364A3 (en) 2008-03-06
JP2009535329A (ja) 2009-10-01
CN101432013B (zh) 2015-01-07
CN102633863A (zh) 2012-08-15
CA2771087A1 (en) 2007-11-08
NZ572255A (en) 2012-03-30
AU2007244004A1 (en) 2007-11-08
US20090162296A1 (en) 2009-06-25
MX2008013769A (es) 2009-02-03
US20120283191A1 (en) 2012-11-08
CN101432013A (zh) 2009-05-13
CN102633863B (zh) 2014-08-06
DK2468292T3 (da) 2020-03-23
ZA200809115B (en) 2009-07-29
US9000125B2 (en) 2015-04-07
EP2468292B1 (en) 2019-12-18

Similar Documents

Publication Publication Date Title
SG171602A1 (en) Use of antisecretory factors for treating intraocular hypertension
WO2007076360A8 (en) (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
WO2003092584A3 (en) Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
WO2009047766A3 (en) Composition and method for the treatment or prevention of glaucoma and ocular hypertension
WO2007035356A3 (en) Glaucoma treatment devices and methods
WO2006124874A3 (en) Inhibitors of b-raf kinase
MX2009001062A (es) Agonistas de ep2.
WO2005002520A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2007108968A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2007016538A3 (en) Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
GEP20084520B (en) Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
WO2008029276A3 (en) Compositions and methods for the treatment of ophthalmic disease
WO2008054639A3 (en) Use of a catechin or polyphenol to treat ocular diseases and infection
WO2004069181A3 (en) Composition for the treatment of intraocular pressure
WO2009111418A3 (en) Ketorolac tromethamine compositions for treating or preventing ocular pain
MY138811A (en) Preventive or therapeutic agent for glaucoma
WO2006044425A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2004043354A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2007127711A3 (en) Abnormal cannabidiols as agents for lowering intraocular pressure
WO2007146136A3 (en) Ophthalmic compositions for treating ocular hypertension
BR0316775A (pt) Novos análogos de benzopirano e seu uso para o tratamento de glaucoma
MX2009004792A (es) Moduladores de la union de pai-1 para el tratamiento de trastornos oculares.
UA94953C2 (en) Ep2 agonists